Acorah Software Products - Accounts Production 19.2.350 false true 31 October 2024 1 November 2023 false 1 November 2024 31 October 2025 31 October 2025 09260860 Mr Baseer Ahmed iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 09260860 2024-10-31 09260860 2025-10-31 09260860 2024-11-01 2025-10-31 09260860 frs-core:CurrentFinancialInstruments 2025-10-31 09260860 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-11-01 2025-10-31 09260860 frs-core:OtherResidualIntangibleAssets 2025-10-31 09260860 frs-core:OtherResidualIntangibleAssets 2024-11-01 2025-10-31 09260860 frs-core:OtherResidualIntangibleAssets 2024-10-31 09260860 frs-core:ShareCapital 2025-10-31 09260860 frs-core:RetainedEarningsAccumulatedLosses 2025-10-31 09260860 frs-bus:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 09260860 frs-bus:FilletedAccounts 2024-11-01 2025-10-31 09260860 frs-bus:SmallEntities 2024-11-01 2025-10-31 09260860 frs-bus:AuditExempt-NoAccountantsReport 2024-11-01 2025-10-31 09260860 frs-bus:SmallCompaniesRegimeForAccounts 2024-11-01 2025-10-31 09260860 frs-bus:Director1 2024-11-01 2025-10-31 09260860 frs-countries:EnglandWales 2024-11-01 2025-10-31 09260860 2023-10-31 09260860 2024-10-31 09260860 2023-11-01 2024-10-31 09260860 frs-core:CurrentFinancialInstruments 2024-10-31 09260860 frs-core:ShareCapital 2024-10-31 09260860 frs-core:RetainedEarningsAccumulatedLosses 2024-10-31
Registered number: 09260860
MEDICURE SCIENTIFIC LIMITED
Unaudited Financial Statements
For The Year Ended 31 October 2025
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—4
Page 1
Balance Sheet
Registered number: 09260860
2025 2024
Notes £ £ £ £
FIXED ASSETS
Intangible Assets 4 30,000 45,000
30,000 45,000
CURRENT ASSETS
Stocks 5 69,000 128,000
Debtors 6 791,707 3,307
Cash at bank and in hand 65,694 786,507
926,401 917,814
Creditors: Amounts Falling Due Within One Year 7 (340,687 ) (342,693 )
NET CURRENT ASSETS (LIABILITIES) 585,714 575,121
TOTAL ASSETS LESS CURRENT LIABILITIES 615,714 620,121
NET ASSETS 615,714 620,121
CAPITAL AND RESERVES
Called up share capital 8 100 100
Profit and Loss Account 615,614 620,021
SHAREHOLDERS' FUNDS 615,714 620,121
Page 1
Page 2
For the year ending 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Mr Baseer Ahmed
Director
20/07/2026
The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
MEDICURE SCIENTIFIC LIMITED is a private company, limited by shares, incorporated in England & Wales, registered number 09260860 . The registered office is 24 Felbrigge Road, Ilford, IG3 8DN.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.
2.3. Intangible Fixed Assets and Amortisation - Other Intangible
Other intangible assets are patent costs It is amortised to the profit and loss account over its estimated economic life of 3 years.
2.4. Stocks and Work in Progress
Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.
2.5. Taxation
Income tax expense represents the sum of the tax currently payable.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
3. Average Number of Employees
Average number of employees, including directors, during the year was: NIL (2024: NIL)
- -
4. Intangible Assets
Other
£
Cost
As at 1 November 2024 45,000
As at 31 October 2025 45,000
Amortisation
As at 1 November 2024 -
Provided during the period 15,000
As at 31 October 2025 15,000
Net Book Value
As at 31 October 2025 30,000
As at 1 November 2024 45,000
Page 3
Page 4
5. Stocks
2025 2024
£ £
Finished goods 69,000 128,000
6. Debtors
2025 2024
£ £
Due within one year
Amounts owed by group undertakings 786,178 -
Other debtors 5,529 3,307
791,707 3,307
7. Creditors: Amounts Falling Due Within One Year
2025 2024
£ £
Trade creditors 4,267 4,268
Other creditors 333,935 336,543
Taxation and social security 2,485 1,882
340,687 342,693
8. Share Capital
2025 2024
£ £
Allotted, Called up and fully paid 100 100
9. Related Party Transactions
Included in creditors falling due within one year is an amount of £329,995 (2024: £332,303) owed to the director. The loan is interest free.
Page 4